How to Evaluate a Pharma Stock: The Complete Investor's Guide

What You'll Learn

By the end of this guide, you'll understand:

• The 12 metrics that matter most when evaluating any Indian pharma stock
• How to read a pharma company's revenue mix and what it tells you
• What US FDA compliance means for a company's financials
• A reusable checklist you can apply to any pharma stock you research

Reading Time: 16 minutes Difficulty Level: Beginner-friendly

---

The Problem With Generic Stock Analysis Frameworks

Most investing guides teach you to check P/E ratio, revenue growth, and profit margins. For most industries, that is a reasonable starting point.

Pharma is different. A pharma company with a P/EP/E Ratio (Price to Earnings)Tells you how many years of current earnings you're paying for when you buy a stock. A P/E of 25 means you pay 25 years of today's profits upfront. High P/E = market expects strong growth; low P/E = slow growth or high risk.See all terms in the glossary of 30 and 15% revenue growth might be a fantastic business, or it might be one FDA Warning LetterFDA Warning LetterA formal FDA notice that a company is seriously non-compliant with manufacturing standards. It blocks new drug approvals from that plant until resolved — and typically wipes 15–20% off the stock price.See all terms in the glossary away from losing 30% of its revenue overnight. Two pharma companies with identical margins might have completely different moatEconomic MoatA sustainable competitive advantage that protects a company's profits from rivals — like a castle's moat. Types include brand loyalty, network effects, switching costs, scale advantages, and regulatory barriers. Warren Buffett's core investing concept.See all terms in the glossary structures: one earns those margins through brand and doctor relationships (durable), the other through a temporary monopoly on a soon-to-expire patent (not durable).

Generic financial analysis misses the things that actually drive pharma stock performance.

This guide teaches you the pharma-specific metrics you need to evaluate any Indian pharmaceutical company. If you haven't already read how India's pharma value chain works, start there first. Understanding the industry structure makes each of these metrics make much more intuitive sense.

---

The Investor's Decision Framework

Imagine you are looking at Sun Pharma and you want to decide whether to invest. Where do you start?

Rather than jumping straight to the P/E ratio, a good pharma analyst asks a sequence of questions:

Walk through these in order and you will have a thorough picture of any Indian pharma company.

---

Metric 1: Revenue Mix

The first thing to understand about any pharma company is where its revenue comes from, because different revenue streams have completely different risk profiles.

Indian pharma companies typically earn revenue from some combination of:

• Domestic formulations: Branded generic drugsBranded GenericsA generic drug sold under a proprietary brand name. Doctors prescribe by brand, not molecule name — this doctor-brand loyalty is a durable competitive moat.See all terms in the glossary sold to Indian doctors and patients. Example: Sun Pharma's Pantocid (acidity), Cipla's Asthalin (asthma inhaler), Dr. Reddy's Omez (gastric). These drugs are prescribed by brand name even though cheaper unbranded generics exist.
• US generics: Generic drugs exported to the US market under ANDA approvalsANDA (Abbreviated New Drug Application)The FDA filing used by generic drug companies to get approval without repeating full clinical trials — they only need to prove their drug behaves the same in the body.See all terms in the glossary. Example: Dr. Reddy's sells over 100 generic molecules in the US, including generic versions of Allegra (allergy) and Prilosec (acidity). Aurobindo and Zydus each earn 40 to 50% of total revenue from this segment alone.
• Emerging markets (EM): Generics sold to markets in Africa, Southeast Asia, Latin America, and Russia/CIS. Example: Dr. Reddy's Russia business sells branded generics like Nise (painkiller) and Ketorol under its own brand — these drugs are as well-known in Russia as Paracetamol is in India. Cipla supplies HIV and tuberculosis drugs to 40-plus African countries.
• API (Active Pharmaceutical Ingredients): Selling the raw active molecule to other pharma companies who turn it into finished pills. Example: Divi's Laboratories supplies APIs for drugs like Naproxen and Gabapentin to Pfizer, Bayer, and other multinationals. Sun Pharma's API division sells to third parties as well as its own formulations business.
• Consumer health / OTC: Brands sold directly to consumers without a doctor's prescription. Example: Mankind Pharma's Gas-O-Fast (antacid), Prega News (pregnancy test kit), and Manforce (condoms) are all OTC consumer brands. Cipla's Nicotex (nicotine gum) is another example.
• Specialty / branded international: Patented or novel drugs sold in the US or Europe at premium prices. Example: Sun Pharma's Ilumya (Rs 8,000 per injection in the US) for psoriasis and Winlevi for acne are specialty drugs with far higher margins than generics. Dr. Reddy's biosimilar Rituximab, sold in Europe, is an early example of Indian specialty pharma.

Why the split matters

Red flag to watch: If a company earns more than 60% of revenue from US generics without a growing specialty pipeline, it is highly exposed to both FDA compliance risk and relentless price erosion from generic-on-generic competition.

What to look for: A well-balanced company might earn 40 to 50% from domestic branded drugs (stable, high-moat), 25 to 35% from exports (US or EM), and 10 to 15% from other segments. Sun Pharma has increasingly shifted towards US specialty drugs (Ilumya, Winlevi) to reduce the pure-generics exposure that suppressed its margins through 2015 to 2020.

Why This Matters: Revenue mix determines the volatility of a pharma company's earnings. A company with 70% domestic branded revenue will have highly predictable earnings. A company with 70% US generics will have lumpy, risk-exposed earnings.

---

Metric 2: EBITDA Margins

EBITDA margin (Earnings Before Interest, Tax, Depreciation, and Amortisation, expressed as a percentage of revenue) tells you how much operating profit the company earns per rupee of revenue.

For Indian pharma companies, here are the benchmarks:

Why margins compress in generics

In the US generics market, when a new generic drug is approved, multiple companies often enter simultaneously. Within 3 to 6 months of launch, prices can drop 60 to 80% from the branded drug price. Within 12 to 24 months, they stabilise at a thin margin above the cost of manufacturing.

This phenomenon (called "day-1 price erosion"Day-1 Price ErosionWhen a generic drug launches in the US, multiple competitors often enter on the same day. Prices can drop 60–80% within months as companies undercut each other. A blockbuster generic that earns 40% margins in year 1 may earn only 15% by year 3 — so US generics revenue must be constantly refreshed with new launches.See all terms in the glossary) means that a company that earns 40% EBITDA margin in year 1 of a generic launch might earn only 15% by year 3. US generics revenue is not an annuity: it constantly needs to be refreshed with new launches.

Where to find margin data: Annual report income statement, quarterly earnings presentations, stock exchange filings.

Red flags to watch: Margins below 15% in a formulation company suggest commoditisation or structural pricing pressure. A sudden margin drop of 4 to 5 percentage points year-on-year often signals a significant FDA issue or a major product losing exclusivity.

Why This Matters: EBITDA margin is the single best quick-read metric for a pharma company's competitive position. If margins are high and stable, the company has pricing power. If they are declining, find out why before investing.

---

Metric 3: R&D Spend as a Percentage of Revenue

Research and Development (R&D) spend tells you how much a company is investing in its future versus harvesting its present.

The Indian pharma average sits between 6 and 8% of revenue, reflecting the industry's shift from simple generics toward complex generics, biosimilars, and specialty drugs.

Important distinction: R&D spend on generic filings (ANDAs in the US) is very different from R&D spend on novel drugs (NCEs, or New Chemical Entities). Generic R&D has a high probability of success (you are copying a proven molecule) but produces a commoditised product. Novel drug R&D has a 5 to 10% success rate but can produce a blockbuster with pricing power.

Always ask: what is the company spending its R&D on? Cipla's R&D is increasingly focused on complex inhalation generics (genuinely difficult to replicate, high-margin). Sun Pharma's specialty pipeline (Ilumya for psoriasis, Winlevi for acne) is novel drug R&D. These carry different risk profiles despite similar R&D ratios.

Where to find this: Annual report, R&D section. Companies typically break down R&D spend by geography and type in their management discussion sections.

Why This Matters: A company spending 1% on R&D is milking existing products. A company spending 10% is building future moats. Knowing which one you're buying matters enormously for 5-to-10-year return expectations.

---

Metric 4: The ANDA Pipeline

An ANDA (Abbreviated New Drug Application) is the approval application a generic drug company files with the US FDA to sell a generic version of a drug in the US.

Every pending ANDA represents a potential future revenue stream. A company with 150 pending ANDAs has a deeper future pipeline than one with 40, all else being equal.

Key terms to understand:

Pending ANDAs: Applications filed with the FDA but not yet approved. The FDA approval time averages 24 to 36 months for standard ANDAs.

Para IV filings: A special type of ANDA where the generic company challenges the original drug's patent, arguing it is invalid or not infringed. This is aggressive and legally risky, but the reward is significant: the first company to file a successful Para IV challenge gets 180 days of exclusive rights to sell that generic in the US. During those 180 days, no other generic can enter, meaning the "first filer" can price at a meaningful premium and capture outsized profits.

First-to-file status: Being the first generic company to file an ANDA for a particular drug gives first-mover advantages, especially for Para IV challenges.

Indian Para IV success stories

Ranbaxy vs. Pfizer (Lipitor, 2011): The most famous Para IV case in Indian pharma history. Ranbaxy filed the first Para IV challenge against Pfizer's Lipitor (atorvastatin) in 2003 (at the time, the world's best-selling drug at $12 billion in annual US sales). After eight years of litigation, Ranbaxy won and launched its generic in November 2011 with full 180-day exclusivity. Analysts estimated Ranbaxy earned $600 million or more in profits during that single exclusivity window, from just one Para IV challenge. This case showed the Indian pharma industry what aggressive IP litigation could achieve.

Dr. Reddy's (Nexium and beyond): Dr. Reddy's has been one of India's most prolific Para IV filers over the past two decades. They secured first-to-file Para IV status on AstraZeneca's Nexium (esomeprazole), one of the world's best-selling heartburn drugs. Dr. Reddy's investor presentations consistently disclose their number of first-to-file applications as a key pipeline metric, typically 10 to 20 active first-to-file opportunities at any given time, representing significant future earnings potential.

Cipla (complex inhalation Para IVs): Cipla has pursued Para IV challenges in a more specialised arena: complex inhaler drugs. Challenging patents on drugs like GSK's Advair (fluticasone/salmeterol) requires not just proving the patent is invalid but also demonstrating that a complex device-drug combination performs equivalently. Cipla's inhalation Para IV efforts, if successful, would give it exclusivity on drugs with billions in annual US sales and serve as proof of its technical capabilities in the hardest-to-copy segment of generics.

How to use this metric

Look for the total number of pending ANDAs, but also look for the number of first-to-file opportunities (especially Para IVs). A company with 20 Para IV first-to-file applications has potentially lucrative "exclusivity windows" coming in the future.

Dr. Reddy's investor presentations, for example, typically disclose the number of pending ANDAs and first-to-file applications. Cipla reports its US ANDA filings and approvals. Sun Pharma's specialty pipeline disclosures show its transition from generics to specialty products.

Where to find this: Company investor presentations, US FDA Orange Book (publicly available at orangebook.fda.gov), annual reports.

Why This Matters: The ANDA pipeline is like an order book for a manufacturing company. It tells you what revenue is coming 2 to 4 years in the future. A rich pipeline means visible growth; an empty pipeline means the company must keep filing to stay relevant.

---

Metric 5: US FDA Compliance Status

This is the most company-specific risk metric in pharma, and one of the most important.

Every Indian pharma plant that exports to the US is subject to periodic inspections by US FDA investigators. The outcome of these inspections can range from routine clearance to severe enforcement actions. Understanding where a company's plants stand is non-negotiable before investing.

The three escalation levels:

Form 483: The lowest level of concern. Issued at the end of an inspection when investigators find observations that may violate GMP (Good Manufacturing Practice) standards. Companies have 15 business days to formally respond with a corrective action plan. A Form 483 alone does not stop new approvals or imports. It is a yellow flag, not a red one.

Warning Letter: Issued when the FDA determines a company has not adequately addressed Form 483 observations, or when violations are serious. A Warning Letter has direct financial consequences: the FDA places all pending ANDAs from that facility in a queue and will not approve new applications until the Warning Letter is resolved. This can freeze a company's US growth pipeline for 12 to 24 months. Stocks often drop 15 to 25% on a Warning Letter announcement.

Import Alert: The nuclear option. The FDA places an Import Alert when it believes products from a facility pose a serious public health risk or when a company has repeatedly failed to comply. Under an Import Alert, US Customs can detain any shipment from that facility without physical examination. Revenue from that plant drops to near-zero.

Historical examples to study:

• Sun Pharma's Halol plant (Gujarat) received a Warning Letter in 2014; it took 2 years to resolve and significantly impacted US generics revenue
• Dr. Reddy's Srikakulam plant faced issues in 2014 to 2015
• Wockhardt's Waluj plant received an Import Alert in 2013, effectively shutting out its US business for years

How to check current status: The US FDA website (fda.gov) maintains a public database of Warning Letters and Import Alerts. Before investing in any Indian pharma company with US exports, check this database. For a deeper explanation of how the FDA inspection process works and what each escalation level means operationally, see the Regulatory Approval section in our India Pharma Value Chain guide.

Why This Matters: No other single event can destroy a pharma company's revenue as quickly as an FDA enforcement action. A Warning Letter on a key plant can suppress earnings for 2 to 3 years. Make FDA compliance status checking a habit before every pharma investment.

---

Metric 6: Domestic Brand Strength

India's domestic pharma market is where the most durable moats exist. Understanding a company's domestic franchise tells you about the stability and defensibility of its earnings.

Branded vs unbranded generics

In India, most drugs sold are technically generics (the original patent has expired), but they are sold under brand names. A company spends years building prescriber relationships, brand recall with doctors, and trust with patients. Once entrenched, these brands are very hard to dislodge even if cheaper generics exist.

The chronic vs acute distinction

Chronic therapy drugs are taken every day for life: blood pressure medications, diabetes drugs, thyroid drugs, psychiatric medications. A patient stabilised on a particular brand of metformin will rarely switch. Chronic drugs provide highly recurring, predictable revenue.

Acute therapy drugs are taken for a short course to treat an illness: antibiotics, antivirals, antipyretics. Prescribing is more opportunistic and switch rates are higher. Revenue is more variable.

A company with a higher share of chronic therapy brands has more predictable domestic revenue. Sun Pharma and Cipla both have strong chronic therapy portfolios (cardiovascular, diabetes, respiratory, psychiatry). This is a significant quality indicator.

How to measure domestic brand strength

The best source is IQVIA (formerly IMS) prescription data, which is widely referenced in analyst reports and company presentations. Look for:

• Company's rank in domestic formulations market (Sun Pharma is No. 1)
• Market share by therapy area
• Number of brands among the top-300 or top-500 drugs by prescription volume

Why This Matters: The domestic branded business is the "sleep well at night" part of an Indian pharma company. While the US business fluctuates with FDA actions and generic pricing, the domestic branded business compounds steadily. Companies with strong domestic franchises deserve a premium valuation.

---

Metric 7: The Medical Representative Network

The size and productivity of a pharma company's Medical Representative (MR) network is a proxy for its domestic competitive reach.

Key numbers to know:

An Indian pharma company with 10,000 MRs has a formidable, hard-to-replicate presence with doctors across the country. Mankind Pharma built its model specifically around having one of the highest MR-to-revenue ratios in the industry, giving it deep reach into Tier 2 and Tier 3 markets where larger competitors had a thinner presence.

Revenue per MR is a useful productivity metric. Divide domestic formulations revenue by total MR headcount. A higher revenue-per-MR indicates either a more productive sales force or better brand premium (often both).

Cost of an MR: Each MR costs approximately Rs 8 to 12 lakh per year all-in (salary, allowances, samples, travel). A company with 10,000 MRs has an annual field force cost of Rs 800 crore to Rs 1,200 crore. This is a large, largely fixed cost that creates operating leverage: as revenue grows, the MR cost as a percentage of revenue falls.

Where to find this: Most companies disclose their MR headcount in annual reports or investor presentations.

Why This Matters: Building a large, effective MR network takes 5 to 10 years and constant investment. A company with a 10,000-strong field force has a distribution moat that a new entrant cannot easily replicate. This is one of Mankind Pharma's key competitive advantages.

---

Metric 8: Working Capital and Cash Conversion

Pharma businesses hold a lot of cash tied up in the working capital cycle. Understanding this is important for assessing the quality of earnings.

What eats working capital in pharma:

Inventory: A pharma company needs to hold raw materials (APIs, excipients), work-in-progress (drugs being manufactured), and finished goods (manufactured drugs awaiting sale). Given the complexity of pharmaceutical manufacturing and the need to maintain buffer stock for continuous supply, pharma companies typically hold 90 to 150 days of inventory.

Receivables (debtors): After selling to distributors or hospitals, the company waits to collect payment. Domestic distributors typically pay in 30 to 60 days. Export markets (especially government tenders in Africa, Russia, or PMJAY in India) can take 90 to 180 days.

Cash Conversion Cycle (CCC) = Inventory days + Receivable days minus Payable days

A lower CCC means the company converts sales to cash faster, requiring less capital locked in the operating cycle.

Comparing companies:

Companies with strong domestic branded businesses tend to have better working capital profiles than pure-export generics companies, because:

• Domestic distributors pay faster than export markets
• Branded drugs command better payment terms
• The distributor network is more established

Red flag to watch: Rapidly rising receivables relative to revenue growth is a warning sign. It can mean the company is extending aggressive credit terms to push sales (sometimes called "channel stuffing") or that export markets are paying slower.

Why This Matters: Two companies with identical EBITDA margins can have very different free cash flow profiles based on working capital efficiency. Cash flow, not reported profit, is what you ultimately own as a shareholder.

---

Metric 9: Debt and Balance Sheet Health

Pharma is fundamentally a cash-generative business with moderate capital intensity. A well-run pharma company should be low-debt.

Benchmarks:

Net debt / EBITDA below 1x: Comfortable. The company can pay off all its debt in less than one year of operating profit.

Net debt / EBITDA of 1x to 2x: Manageable, but watch for how the debt was incurred.

Net debt / EBITDA above 2x: Needs explanation. Usually the result of a large acquisition.

The acquisition watch list

Most large pharma debt in India was incurred through acquisitions:

• Sun Pharma's 2015 acquisition of Ranbaxy (a Rs 15,000 crore deal) saddled it with legacy liabilities and manufacturing compliance issues for years
• Strides Pharma has made multiple acquisitions over the years
• Mankind Pharma's acquisition of BSV Group's branded brands in 2024 added some leverage

Acquisitions in pharma can be value-creating (adding brands, plant capacity, geographic reach) or value-destroying (overpaying for a business with hidden liabilities, especially legacy FDA issues). Always ask: what was acquired, why, and what has the track record been?

Cash position and dividend history

A pharma company with a strong domestic franchise and clean exports should generate substantial free cash flow. Sun Pharma generates over Rs 5,000 crore of free cash flow annually. Dr. Reddy's and Cipla are similarly cash-generative. Companies that consistently pay dividends and buyback shares are signalling financial confidence.

Why This Matters: A pharma company carrying high debt has less flexibility to invest in R&D, weather an FDA crisis, or make opportunistic acquisitions. Balance sheet health is a resilience metric.

---

Metric 10: NPPA Exposure

The National Pharmaceutical Pricing Authority (NPPA) regulates prices on essential medicines listed in India's National List of Essential Medicines (NLEM). Understanding how exposed a company's domestic portfolio is to NPPA-controlled prices is important for forecasting margins.

What is price-controlled?

The NLEM currently covers approximately 384 drug formulations, typically basic antibiotics, cardiovascular drugs, diabetes medications, and tuberculosis treatments. These are generally the older, well-established molecules.

For price-controlled drugs, the NPPA sets a ceiling price (calculated based on the market-weighted average price of all brands selling that drug). Manufacturers cannot charge above this ceiling. The ceiling is revised annually, usually in line with the Wholesale Price Index.

What is not price-controlled?

Newer molecules, specialty drugs, and most OTC consumer health products are not on the NLEM. Companies that have successfully moved their portfolios toward newer, non-NLEM molecules are less exposed to pricing authority interventions.

How to estimate NPPA exposure

Some companies disclose what percentage of their domestic formulations revenue comes from scheduled (price-controlled) drugs. Analysts at brokerage firms also estimate this using IQVIA prescription data. As a rough benchmark: a company with 30% NLEM exposure is fairly typical; one with 50% or above has above-average pricing risk.

Why This Matters: An NPPA price cut of 5 to 10% on scheduled medicines effectively reduces that portion of domestic revenue by the same percentage overnight. For a company with 35% domestic NLEM exposure, a 10% price cut reduces total revenues by roughly 3 to 4%. This is not catastrophic, but it is significant and unpredictable.

---

Metric 11: Return Ratios

After understanding the business model and risks, the next question is whether the company actually earns good returns on the money it deploys. You can have a great brand, a clean FDA record, and a strong domestic franchise — but if the business is consuming capital faster than it generates returns, it is not a great investment. Return ratios are how you measure this.

There are three ratios to look at together: ROCEROCE (Return on Capital Employed)Measures how efficiently a company generates profit from all the capital it uses — both equity and debt. ROCE above 20% is generally excellent. The best businesses compound ROCE above 25% for decades.See all terms in the glossary, ROEROE (Return on Equity)Profit generated for every rupee or dollar of shareholders' money invested. ROE above 15% is generally good. Watch out: high ROE driven by heavy debt is misleading — check ROCE alongside it.See all terms in the glossary, and Asset Turnover. Each one reveals a different dimension of the same underlying question: how efficiently does this company turn capital into profit?

---

ROCE (Return on Capital Employed): The Most Honest Measure

ROCE = EBIT / Capital Employed

Break this down in plain English:

Capital Employed is the total long-term money tied up in the business: factories, R&D labs, regulatory filings, equipment, and the working capital needed to run operations. Think of it as "everything the business needs to function, minus short-term borrowings." For a pharma company, this includes the WHO-GMP-certified manufacturing plant (which might cost Rs 300 to 800 crore to build), the regulatory team that filed 200 ANDAs over a decade, and the medical representative network that calls on 50,000 doctors.

EBIT (Earnings Before Interest and Tax) is the operating profit the business generates before paying lenders or the government. It is the "raw output" of the business engine, before financing choices cloud the picture.

So ROCE asks: for every Rs 100 of capital this company has tied up, how many rupees of operating profit does it generate each year?

Why ROCE matters specifically in pharma

Pharma is unusual in that it requires large, lumpy upfront capital (manufacturing plants, clinical trials, regulatory approvals) but then generates recurring, high-margin revenue for years if the product has a moat. A branded drug that doctors prescribe by name every month for the next 10 years generates revenue from capital that was deployed only once.

Compare two factories of the same cost:

• A steel plant built for Rs 3,000 crore might generate Rs 200 crore of EBIT: ROCE of roughly 7%.
• A pharma plant built for Rs 500 crore that produces branded cardiac drugs prescribed by 20,000 cardiologists might generate Rs 175 crore of EBIT: ROCE of 35%.

The pharma plant wins because the product has a pricing moat (doctor loyalty, brand recall, chronic therapy repeat prescription) that the steel plant does not. High ROCE in pharma is the mathematical fingerprint of a moat.

For Indian pharma companies:

• ROCE above 25%: Excellent. The company has a strong competitive position.
• ROCE of 18 to 25%: Good. Typical for established domestic-focused pharma.
• ROCE of 12 to 18%: Average. May signal heavy capital investment in new plants or acquisitions dragging returns temporarily.
• ROCE below 12%: Below-average. Check whether R&D capitalisation or recent acquisitions are distorting the number, or whether the business model is genuinely weaker.

---

ROE (Return on Equity): The Shareholders' Lens

ROE = Net Profit / Shareholders' Equity

Where ROCE looks at the whole capital base (equity plus debt), ROE only looks at the equity portion: the money that belongs to shareholders. It asks: for every Rs 100 of shareholders' money in the business, how many rupees of net profit does the company earn?

Typical range for good Indian pharma companies: 15 to 25%.

The DuPont breakdown: why ROE can mislead you

ROE can be high for three very different reasons, and not all of them are good:

1. High profit margins (genuinely good): The company earns Rs 22 of net profit for every Rs 100 of sales. This reflects pricing power — doctors prescribe the brand by name, or the specialty product has no generic competition.

2. High asset efficiency (genuinely good): The company squeezes Rs 1.20 of revenue out of every Rs 1 of assets, meaning existing factories are running near capacity with minimal idle capital.

3. High financial leverage (caution required): The company has borrowed heavily, which mathematically amplifies ROE because equity is the denominator. A company with Rs 500 crore of equity and Rs 2,000 crore of debt looks like it has high ROE — but it is actually taking on financing risk to inflate the ratio.

The diagnostic: always look at ROCE alongside ROE. If ROCE is 14% but ROE is 28%, the company is almost certainly using debt to inflate its equity returns. That is fragile. If both ROCE and ROE are high (say, 24% and 22% respectively), the returns are genuine and driven by the business, not leverage.

Watch for: high ROE driven by high leverage (this is not high-quality ROE). You want ROE driven by high margins and asset turns, not by financial leverage.

---

Asset Turnover: How Hard Are the Assets Working?

Asset Turnover = Revenue / Total Assets

This ratio tells you how much revenue each rupee of assets generates. A company with Rs 10,000 crore of assets generating Rs 9,000 crore of revenue has an asset turnover of 0.9x. One generating Rs 12,000 crore from the same assets has 1.2x.

What this means in pharma specifically

Pharma is more capital-intensive than software (which has near-zero physical assets) but less capital-intensive than industries like steel, cement, or power (which require enormous physical infrastructure per rupee of revenue). A typical Indian formulation company has asset turns of 0.8 to 1.2x.

Here is what the numbers tell you:

Asset turnover below 0.7x usually means the company has recently expanded capacity (built new plants, made a large acquisition) and that capacity is not yet generating full revenue. This can be temporary — judge whether the new capacity has a demand driver behind it. If a company just built a new US FDA-approved plant to supply a contract for a large US buyer, low asset turnover now may mean high revenue later.

Asset turnover above 1.2x means existing factories are running efficiently and generating strong revenue output. This is usually a good sign, but it can also mean the company is near its capacity ceiling and will need fresh capital expenditure soon to support further growth.

Putting the three ratios together

The table below shows how different pharma business profiles score across these three ratios:

The post-acquisition row is the one to watch: ROE looks impressive, but the high leverage is why. Subtract the debt, and the underlying business returns are ordinary.

---

Trend Matters More Than Any Single Year

A pharma company with high, stable ROCE over many years is compounding value. A company with declining ROCE may be over-investing in capacity that isn't generating adequate returns, or it may be absorbing the aftermath of an acquisition.

A useful mental model:

• ROCE trending upward (say, 15% to 24% over 5 years): Management is deploying capital well. Each new investment is generating better returns than the last. This is the signature of a business building its moat.
• ROCE flat (22% consistently over 5 years): A stable, well-run business. The moat exists and is being maintained.
• ROCE declining (28% to 16% over 5 years): Something has changed. Either the core business is under pressure (US generics price erosion), or capital is being deployed badly (expensive acquisitions earning weak returns). This needs explanation before investing.

Always check the 5-year trend in ROCE, not just the most recent number. A company with ROCE of 22% today that was at 30% three years ago is a very different situation from a company that has been consistently at 22% for five years.

---

Metric 12: Valuation Multiples

With all the above understood, the final step is asking: is the current stock price fair?

Common pharma valuation multiples:

P/E ratio (Price to Earnings): Pharma stocks in India typically trade at 25 to 45x earnings, reflecting the market's recognition of their stable, recurring revenue and moat characteristics. Companies with specialty pipelines (Sun Pharma) trade at the higher end; pure generics trade at the lower end.

EV/EBITDA (Enterprise Value to EBITDA): More useful than P/E when companies have different capital structures. Indian pharma typically trades at 18 to 30x EBITDA.

Price/Sales: Useful for early-stage pharma companies that are not yet profitable. Rarely applicable to large Indian pharma.

How to use comparables

The most useful comparison is against the company's own historical valuation range and against close peers. Sun Pharma at 35x earnings might look expensive on an absolute basis but reasonable if it historically traded at 30 to 45x and currently has a better specialty pipeline than it did 3 years ago.

Compare against: peer group average P/E (BSE Healthcare Index components), the stock's own 5-year average P/E, and what growth rate is implied by the current multiple.

A note on pharma P/E

Pharma earnings can be distorted by one-time items: FDA-related write-offs, litigation settlements (often from Para IV challenges), impairment of acquired goodwill. Use "adjusted earnings" or EBITDA (which is pre-interest and pre-depreciation) for more comparable period-to-period analysis.

Why This Matters: Buying a great pharma business at the wrong price still produces poor returns. A company with 15% earnings growth trading at 50x P/E needs to maintain that growth for 5-plus years just to justify its current price. Valuation discipline is essential even for high-quality businesses. For a full framework on when to buy, see our guide to valuation and when to buy.

---

The Pharma Stock Evaluation Checklist

Use this as a quick-reference before researching any Indian pharma company:

---

Key Takeaways

• Pharma companies need sector-specific metrics: generic financial ratios miss the industry's key drivers and risks
• Revenue mix is the foundation: understand what the company sells, to whom, and in which geography before anything else
• US FDA compliance is a binary risk: a clean FDA record is table stakes; a Warning Letter can freeze growth for 2-plus years
• EBITDA margins above 20% and stable ROCE above 20% are the hallmarks of a well-positioned Indian pharma company
• The ANDA pipeline is the forward-looking growth indicator: count pending ANDAs and look for Para IV first-to-file opportunities
• Domestic branded franchises, especially in chronic therapy, are the most durable moats in Indian pharma
• NPPA price controls are a persistent, low-level headwind: companies moving their portfolio toward newer, non-NLEM molecules are better positioned
• Always cross-check valuation against peers and the company's own historical range, not just absolute P/E levels

---

What to Read Next

• From Lab to Pharmacy: How India's Pharma Value Chain Works
• Drug Patents, Generic Moats, and India's Global Edge
• Valuation 101: When to Buy a Stock
• How to Read a Company's Annual Report
• Understanding Economic Moats